PPBTPURPLE BIOTECH LTD. · NASDAQ Capital Market (ADSs); ordinary shares dual-listed on TASE
Effective Supply — the real overhang

From what's tradeable today to what's realistically coming. Bigger = more selling pressure ahead.

1.62M
Reported Float
932.3K
Tradeable Now
(estimated float)
▲ data says 1.62Moverstated 74%
1.62M
Effective Supply
8.19M
Fully Diluted
Dilution risk4/10
CONFIDENCE: LOW
MODERATEAssessed Aug 24, 2026Trigger: Scheduled refreshCRITICALUnreconciled share count / possible unfiled mid-2026 issuanceHIGHWarrant overhang subject to demonstrated repricing/inducement

Score is held down by a genuinely clean CURRENT instrument stack and pushed up by everything else. Convertibles/preferreds (40% weight) = 0: there are zero convertible notes, zero outstanding preferred (blank-check authorization only), and zero variable-rate instruments — the September 2025 purchase agreement even contains an express covenant barring price-reset financings for one year post-closing. Warrant overhang (30% weight) = 4: 1,248,089 ADS of live warrants equal roughly 77% of the reported float, but the cheapest strike is $10.00 versus a $1.57 ADS price (6.4x out of the money) and the weighted average is $13.79 — under the rubric that is near-zero immediate risk, marked up only because PPBT has repriced out-of-the-money warrants down to market TWICE (October 2023: $1,800/$5,600 → $250; July 2024: $250-$4,000 → $72) and then issued fresh warrants on top, so the $10 strike is not a real ceiling. Recent activity (20% weight) = 7: 259.5% ordinary-share growth during 2025 (517.1M → 1.859B), a $6.0M gross F-1 offering on 2025-09-05, $1.13M of Jefferies ATM sales in 2025, and an unreconciled 5.9M ADS gap between the last filed count and the current data-service count that most plausibly reflects a Q2/Q3 2026 raise. Historical pattern (10% weight) = 10: four consolidation/ADS-ratio events (2019 1:20 share consolidation, 2020 1:10, 2024 1:20, 2026 1:10 — cumulative ~40,000:1), continuous H.C. Wainwright-agented financing every 6-9 months since 2020, and two warrant-inducement repricings. Weighted result 3.6, rounded to 4. The forward risk is NOT existing paper — it is the next best-efforts Form F-1 offering, which bypasses the $824,331 baby-shelf ceiling entirely, exactly as the September 2025 deal did.

Share Structure

Float to Fully Diluted Breakdown

LIKELY STALE

Reported float from Insight Sentry (NASDAQ:PPBT), ADS units, as-of date unknown. Adjusted based on SEC filing analysis.

Float Discrepancy: our SEC analysis shows 932K vs 1.62M reported — overstated 74%

Three irreconcilable numbers. (1) Filing-anchored: 909,941 ADS non-affiliate float / 932,274 ADS outstanding as of 2026-05-20. (2) Insight Sentry float: 1,619,223 ADS — 78% above filed outstanding. (3) Insight Sentry outstanding: 6,872,037 ADS — 637% above filed outstanding, implying 13.7 billion ordinary shares. The feed's float/outstanding ratio (23.6%) is also implausible for an issuer that is ...

Reported Float1.62M19.8%
Warrants1.31M15.9%
common1.20M shares at $10
placement_agent42K shares at $12.5
common25K shares at $80
common31K shares at $80
placement_agent2K shares at $90
placement_agent3K shares at $75
placement_agent2K shares at $287.5
pre-funded0 shares at $0.001
Other69K0.8%
Options / RSUs69K shares
≈ Estimated Actual Float

Reported float + filing adjustments

1.62M

LOW confidence

Pending Shares as % of Float113.8%

Registered and convertible shares that could enter the float relative to current float size.

Fully Diluted8.19M100%

Share estimates are approximate. Convertible share counts based on current price. Review SEC filings for exact terms.

See the full breakdown

Red flags, financing counterparties, the deal timeline, and every SEC filing — free with an account.

Sign in to continue
Dilution profile
Reverse splits (4)
  • 1-for-20·Jan 4, 2019~8 yr ago
  • 1:10 (ADS ratio 1:1 → 1:10)·Aug 21, 2020~6 yr ago
  • 1:20 (ADS ratio 1:10 → 1:200)·Sep 17, 2024~2 yr ago
  • 1:10 (ADS ratio 1:200 → 1:2,000)·Mar 2, 2026~6 mo ago
Active mechanisms
  • H.C. Wainwright At The Market Offering Agreement dated 2025-09-19 — $824,331 remaining capacity, 3.0% commission, zero drawn as of 2026-05-20 (~525,000 ADS at $1.57)
  • Form F-3 shelf 333-268710 plus replacement F-3 filed 2026-05-20 — $184.4M nominally unsold, throttled to $824,331 by General Instruction I.B.5 while public float is under $75M
  • Best-efforts Form F-1 offerings with H.C. Wainwright — the actual funding channel; NOT subject to the baby-shelf cap (used for $6.0M on 2025-09-05)
  • Warrant repricing / inducement transactions — demonstrated twice (Oct 2023, Jul 2024); 1,248,089 ADS of out-of-the-money warrants are candidates
  • 2016 Equity Incentive Plan — 79,620,500 ordinary shares under option and 58,886,430 ordinary shares under RSUs (69,253 ADS-equivalent combined)
  • ADS ratio changes as a bid-price remedy — used three times, most recently 2026-03-02

Market Data

Price

$1.66

Market Cap

$10.83M

Outstanding

6.37M

Float

1.62M

Avg Volume

31.0K

Exchange: NASDAQ|Source: Insight Sentry